Ikena Oncology has filed a patent for AHR agonists, their compositions, and methods of use. GlobalData’s report on Ikena Oncology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ikena Oncology, Cancer treatment biomarkers was a key innovation area identified from patents. Ikena Oncology's grant share as of September 2023 was 10%. Grant share is based on the ratio of number of grants to total number of patents.
Ahr agonists and their use in compositions and methods
A recently filed patent (Publication Number: US20230295147A1) describes a compound of Formula (I) and its various derivatives. The compound, along with its pharmaceutically acceptable salts, can be used in the treatment, prevention, or reduction of the risk of angiogenesis implicated disorders and inflammatory disorders.
The patent claims cover a range of compounds, including those with substituted phenyl rings (Ring B and Ring C) and specific variations of the compound (Formulas II, III, IV, V, VIII, and X). The compounds can be administered to patients in the form of a pharmaceutical composition, which includes a pharmaceutically acceptable carrier, adjuvant, or vehicle.
The disclosed method involves administering the compound or its pharmaceutically acceptable salt to a patient for the treatment, prevention, or risk reduction of angiogenesis implicated disorders or inflammatory disorders. Angiogenesis implicated disorders refer to conditions where abnormal blood vessel growth occurs, such as cancer, macular degeneration, and diabetic retinopathy. Inflammatory disorders encompass a wide range of conditions characterized by inflammation, such as rheumatoid arthritis, asthma, and inflammatory bowel disease.
The patent provides a potential solution for the treatment and prevention of these disorders by utilizing the compound of Formula (I) and its derivatives. The compound's specific structure and variations make it a promising candidate for further development and research in the field of pharmaceuticals.
It is important to note that the information provided is solely based on the claims made in the patent and does not include any additional data or research findings. Further investigation and clinical trials would be necessary to determine the efficacy and safety of the compound and its derivatives in treating angiogenesis implicated disorders and inflammatory disorders.
To know more about GlobalData’s detailed insights on Ikena Oncology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
